Ablynx NV News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.10.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
16.10.17	ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER (GlobeNewswire)
13.10.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
06.10.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
02.10.17	ABLYNX FILES REGISTRATION STATEMENT FOR A PROPOSED GLOBAL OFFERING (GlobeNewswire)
02.10.17	ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP (GlobeNewswire)
14.09.17	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
07.09.17	ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON (GlobeNewswire)
30.08.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
30.08.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
24.08.17	ABLYNX ANNOUNCES 2017 HALF YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE (GlobeNewswire)
17.08.17	ABLYNX WILL ANNOUNCE ITS 2017 HALF YEAR RESULTS WITH WEBCAST ON 24 AUGUST 2017 (GlobeNewswire)
11.08.17	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
26.07.17	ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP (GlobeNewswire)
24.07.17	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
20.07.17	ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES (GlobeNewswire)
17.07.17	ABLYNX PROPOSES APPOINTMENT OF MRS HILDE WINDELS AS A NEW INDEPENDENT DIRECTOR (GlobeNewswire)
23.12.16	FMR LLC ANNOUNCE 9.16% SHAREHOLDING IN ABLYNX (GlobeNewswire)
30.11.16	ABLYNX ACHIEVES FIRST MILESTONE AS PART OF COLLABORATION WITH NOVO NORDISK (GlobeNewswire)
23.11.16	ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2016 AND A YEAR-TO-DATE BUSINESS UPDATE (GlobeNewswire)
18.11.16	FMR LLC ANNOUNCE 9.10% SHAREHOLDING IN ABLYNX (GlobeNewswire)
10.11.16	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
09.11.16	ABLYNX TO PRESENT AT THE JEFFERIES LONDON HEALTHCARE CONFERENCE 2016 (GlobeNewswire)
21.10.16	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
20.10.16	ABLYNX OUTLINES NEXT STEPS FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS (GlobeNewswire)
12.10.16	ABLYNX ANNOUNCES SECOND EXTENSION OF ITS ION CHANNEL RESEARCH COLLABORATION WITH MERCK & CO., INC. (GlobeNewswire)
11.10.16	FMR LLC ANNOUNCE 9.22% SHAREHOLDING IN ABLYNX (GlobeNewswire)
10.10.16	ABLYNX INITIATES A PHASE III FOLLOW-UP STUDY OF ITS FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, FOR THE TREATMENT OF ACQUIRED TTP (GlobeNewswire)
29.09.16	ABLYNX'S FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, MAY HAVE THE POTENTIAL TO REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH ACQUIRED TTP (GlobeNewswire)
15.09.16	ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM OPPENHEIMER FUNDS, INC. (GlobeNewswire)
06.09.16	ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM GAM HOLDING AG, GAM INTERNATIONAL MANAGEMENT LIMITED AND TAUBE HODSON STONEX PARTNERS LLP (GlobeNewswire)
25.08.16	ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE (GlobeNewswire)
17.08.16	ABLYNX WILL ANNOUNCE ITS 2016 HALF YEAR RESULTS WITH WEBCAST ON 25 AUGUST 2016 (GlobeNewswire)
12.08.16	ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM ADRIANUS VAN HERK ANDVAN HERK INVESTMENTS B.V. (GlobeNewswire)
09.08.16	ABLYNX REPORTS COMPELLING TOPLINE PHASE IIb STUDY RESULTS WITH ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, IN RA PATIENTS, CONFIRMING ITS BEST-IN-CLASS POTENTIAL (GlobeNewswire)
04.08.16	BANK OF AMERICA CORPORATION ANNOUNCE 5.24% SHAREHOLDING IN ABLYNX (GlobeNewswire)
20.07.16	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
07.07.16	ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB (ALX-0061), AS A MONOTHERAPY IN RA (GlobeNewswire)
16.06.16	CORRECTION TRANSPARENCY NOTIFICATION - ADRIANUS VAN HERK ANNOUNCES 3.02% SHAREHOLDING IN ABLYNX (GlobeNewswire)
16.06.16	VAN HERK INVESTMENTS ANNOUNCE 3.02% SHAREHOLDING IN ABLYNX (GlobeNewswire)
14.06.16	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
10.06.16	PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
03.06.16	ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES HEALTHCARE CONFERENCE 2016 (GlobeNewswire)
26.05.16	ABLYNX TO PRESENT A POST-HOC ANALYSIS OF THE PHASE II TITAN STUDY WITH CAPLACIZUMAB IN ACQUIRED TTP PATIENTS AT THE 21st CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (GlobeNewswire)
13.05.16	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
12.05.16	ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2016 AND PROVIDES BUSINESS UPDATE YEAR-TO-DATE (GlobeNewswire)
03.05.16	ABLYNX REPORTS POSITIVE TOP LINE RESULTS FOR ITS INHALED ANTI-RSV NANOBODY (ALX-0171) IN A PHASE I/IIa STUDY IN INFANTS HOSPITALISED WITH AN RSV INFECTION (GlobeNewswire)
29.04.16	ABLYNX ANNOUNCES MILESTONE IN DRUG DISCOVERY COLLABORATION (GlobeNewswire)
22.04.16	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
21.04.16	ABLYNX TO RECEIVE AN €8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS A PHASE I STUDY WITH AN ANTI-CX3CR1 NANOBODY (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	545.60	2.17 %	K V
Sika	235.80	1.51 %	K V
CieFinRichemont	127.65	1.43 %	K V
Part Grp Hldg	1’299.50	1.33 %	K V
Holcim	91.86	1.15 %	K V
Roche Hldg G	254.50	-0.66 %	K V
Lonza Grp	525.00	-0.72 %	K V
Sonova Hldg	297.70	-1.03 %	K V
Alcon	77.12	-1.20 %	K V
Swiss Life Hldg	690.40	-4.69 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ablynx NV

Aktien Top/Flop

Meistgelesene Nachrichten